ライフサイエンスコーパス: anaplastic large-cell lymphoma

1 NMT1 and expression of CD30 (the hallmark of anaplastic large-cell lymphoma).

2 dvances made for patients with CD30-positive anaplastic large cell lymphoma.

3 malignant cells of Hodgkin's lymphoma and by anaplastic large cell lymphoma.

4 ssed from lymphomatoid papulosis to systemic anaplastic large cell lymphoma.

5 ents for the treatment of advanced cutaneous anaplastic large cell lymphoma.

6 ding angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma.

7 RL/lpr mice and most closely resembled human anaplastic large cell lymphoma.

8 phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

9 es, including classical Hodgkin lymphoma and anaplastic large cell lymphoma.

10 ic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.

11 was observed in a patient with alk-positive anaplastic large-cell lymphoma.

12 th anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma.

13 target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

14 n children with refractory solid tumours and anaplastic large-cell lymphoma.

15 ne marrow and blood samples of patients with anaplastic large-cell lymphoma.

16 tric inflammatory myofibroblastic tumors and anaplastic large cell lymphomas.

17 l characteristics of primary patient-derived anaplastic large cell lymphomas.

18 n of tumors indistinguishable from patients' anaplastic large cell lymphomas.

19 30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas.

20 n of tumors indistinguishable from patients' anaplastic large-cell lymphomas.

21 ophenotype characteristic of patient-derived anaplastic large-cell lymphomas.

22 Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell ly

23 ma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia

24 Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides

25 ral T-cell non-Hodgkin lymphoma, except ALK+ anaplastic large cell lymphoma, 18 to 60 years, all stag

26 (lymphomatoid granulomatosis), 12/19 T-cell anaplastic large-cell lymphomas, 2/12 nodal peripheral T

27 In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entit

28 One patient with cutaneous anaplastic large cell lymphoma (8 mg/kg) achieved a comp

29 All seven patients without anaplastic large-cell lymphoma achieved CR.

30 erfamily whose expression is up-regulated on anaplastic large cell lymphoma (ALCL) and Hodgkin lympho

31 leading to the neoplastic transformation of anaplastic large cell lymphoma (ALCL) and the Reed-Stern

32 vasion and contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely

33 olesterol auxotrophy, particularly in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines and pri

34 We used various ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to eval

35 normal and malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells.

36 WASP and WIP is frequently low or absent in anaplastic large cell lymphoma (ALCL) compared to other

37 Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ide

38 The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and a

39 Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) frequently carries

40 onal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound c

41 A minority of LyP patients progress to anaplastic large cell lymphoma (ALCL) in which skin lesi

42 Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive

43 Anaplastic large cell lymphoma (ALCL) is a distinct clin

44 Anaplastic large cell lymphoma (ALCL) is a distinct enti

45 Anaplastic large cell lymphoma (ALCL) is a highly prolif

46 Anaplastic large cell lymphoma (ALCL) is a mature T cell

47 Anaplastic large cell lymphoma (ALCL) is a mature T-cell

48 Anaplastic large cell lymphoma (ALCL) is a peripheral T-

49 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive C

50 Anaplastic large cell lymphoma (ALCL) is an aggressive n

51 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive T

52 Anaplastic large cell lymphoma (ALCL) is composed of lar

53 Anaplastic large cell lymphoma (ALCL) is the most common

54 In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearra

55 ntified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ A

56 me clone was detected in LyP lesions and the anaplastic large cell lymphoma (ALCL) of 2 patients and

57 anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large cell lymphoma (ALCL) patients.

58 Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) relapse.

59 The incidence rate of primary breast anaplastic large cell lymphoma (ALCL), a complication as

60 In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtyp

61 Anaplastic large cell lymphoma (ALCL), an aggressive CD3

62 Several paediatric malignancies, including anaplastic large cell lymphoma (ALCL), inflammatory myof

63 with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL), the single agent

64 model for the biology and treatment of CD30+ anaplastic large cell lymphoma (ALCL), we transplanted l

65 nase (NPM-ALK) are detected in 50% to 70% of anaplastic large cell lymphoma (ALCL), which is a T/null

66 nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line

67 in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

68 gnancies, including Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

69 ne product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL).

70 , which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL).

71 oma kinase (ALK) consistent with a null cell anaplastic large cell lymphoma (ALCL).

72 roliferation and malignant transformation of anaplastic large cell lymphoma (ALCL).

73 neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

74 er, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL).

75 e in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL).

76 s with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL).

77 nt of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

78 were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).

79 dominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory

80 ) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposi

81 The subset of CD30-positive anaplastic large cell lymphomas (ALCL) with the NPM-ALK

82 vely active nucleophosmin-ALK oncoprotein in anaplastic large cell lymphomas (ALCL).

83 ung cancers (NSCLC) and approximately 70% of anaplastic large cell lymphomas (ALCL).

84 us lymphoid-derived neoplasias, most notably anaplastic large-cell lymphoma (ALCL) and Hodgkin's lymp

85 arget for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory m

86 defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell

87 lastic lymphoma kinase-positive (NPM-ALK(+)) anaplastic large-cell lymphoma (ALCL) as model system, w

88 her variants) are expressed in many cases of anaplastic large-cell lymphoma (ALCL) but are absent fro

89 Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(

90 d neoplasms, was specifically found in all 4 anaplastic large-cell lymphoma (ALCL) cell lines, but no

91 Anaplastic large-cell lymphoma (ALCL) frequently carries

92 30% and 50% of patients with advanced-stage anaplastic large-cell lymphoma (ALCL) harbor the balance

93 ALK chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well def

94 Anaplastic large-cell lymphoma (ALCL) is a clinical and

95 Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently desc

96 Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lympho

97 Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive s

98 Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by s

99 The non-Hodgkin lymphoma (NHL) subtype anaplastic large-cell lymphoma (ALCL) is frequently asso

100 blastoma protein (Rb) in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is unknown.

101 ostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown.

102 LK) chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is well establishe

103 Anaplastic large-cell lymphoma (ALCL) of T- or null-cell

104 Anaplastic large-cell lymphoma (ALCL) provides an excell

105 Anaplastic large-cell lymphoma (ALCL) represents a heter

106 o in the hematologic malignancy ALK-positive anaplastic large-cell lymphoma (ALCL) resistant to ALK-s

107 and is downregulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.

108 Anaplastic lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded.

109 Anaplastic large-cell lymphoma (ALCL) was initially reco

110 anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell

111 -16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30

112 ents aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblasti

113 2;5)(p23;q35) translocation, associated with anaplastic large-cell lymphoma (ALCL), results in the pr

114 In anaplastic large-cell lymphoma (ALCL), the (2;5) chromos

115 t of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jaco

116 a kinase (ALK) in patients with ALK-positive anaplastic large-cell lymphoma (ALCL).

117 plays an important pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL).

118 -FLIP) may contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL).

119 mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL).

120 of galectin-3 in all of the 8 cases of Ki-1+ anaplastic large-cell lymphoma (ALCL).

121 th anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL).

122 type of human lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-posit

123 oma [LBCL], 7 Burkitt's lymphoma [BL], and 4 anaplastic large cell lymphoma [ALCL]), and 25 nonmalign

124 gioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, wit

125 K+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC

126 Anaplastic large cell lymphomas (ALCLs) are caused by ch

127 The majority of pediatric anaplastic large cell lymphomas (ALCLs) carry the t(2;5)

128 Anaplastic Large Cell Lymphomas (ALCLs) carry translocat

129 Anaplastic large cell lymphomas (ALCLs) frequently carry

130 AT3 activation in lymphomas, with a focus on anaplastic large cell lymphomas (ALCLs), which are known

131 oncogenic event in the pathogenesis of most anaplastic large cell lymphomas (ALCLs).

132 ncluding anaplastic lymphoma kinase (ALK)(-) anaplastic large cell lymphomas (ALCLs).

133 ving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs).

134 for anaplastic lymphoma kinase (ALK)- nodal anaplastic large cell lymphomas (ALCLs; n = 24) were obt

135 Anaplastic large-cell lymphomas (ALCLs) are a group of c

136 Primary cutaneous and primary nodal CD30+ anaplastic large-cell lymphomas (ALCLs) are distinct cli

137 Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;

138 Anaplastic large-cell lymphomas (ALCLs) encompass at lea

139 hat drives the survival and proliferation of anaplastic large-cell lymphomas (ALCLs).

140 nd anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite t

141 Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique

142 t was associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive.

143 In contrast, the malignant cells in anaplastic large cell lymphoma and most high-grade tumor

144 s highly dependent on ALK activity in ALK(+) anaplastic large cell lymphoma and non-small-cell lung c

145 n partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibro

146 harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibro

147 CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some

148 e aberrantly expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung c

149 RC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive

150 lymphomas (14 large-B-cell lymphomas and 10 anaplastic large-cell lymphomas), and 15 highly aggressi

151 phomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases.

152 g PTCL NOS, angioimmunoblastic, ALK-negative anaplastic large cell lymphoma, and enteropathy-associat

153 (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) an

154 of PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemi

155 idging large-cell immunoblastic lymphoma and anaplastic large-cell lymphoma, and all 12 cases studied

156 phomas, diffuse large cell B-cell lymphomas, anaplastic large-cell lymphomas, and Epstein-Barr virus-

157 g PTCL, not otherwise specified (PTCL, NOS), anaplastic large-cell lymphomas, and T-follicular helper

158 We also examine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cel

159 Rare histologies include Ki-1 anaplastic large cell lymphoma, angiotropic large cell l

160 plastic lymphoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely unders

161 Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common t

162 ocentric lymphomas of T or NK phenotype, and anaplastic large-cell lymphomas are cytotoxic T-or NK-ce

163 events involved in breast implant-associated anaplastic large cell lymphoma (BI-ALCL) remain elusive.

164 incidence rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) at a high-volu

165 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare

166 Though rare, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a CD30+ T-cel

167 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare periph

168 Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a CD30-posi

169 Breast-implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is an uncommon

170 e treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by h

171 chromosome breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM

172 Breast implant-associated anaplastic large cell lymphoma (breast implant ALCL) is

173 e treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Admi

174 MF), and three of 10 primary cutaneous CD30+ anaplastic large-cell lymphoma (C-ALCL).

175 In anaplastic large cell lymphoma, CD30 triggering induces

176 In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malig

177 ymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary pa

178 optotic anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectop

179 but not in NPM/ALK-negative, patient-derived anaplastic large cell lymphoma cell lines.

180 th of a subset of acute myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing ce

181 g peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without

182 diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leuk

183 d by the t(2;5) translocation in a subset of anaplastic large cell lymphomas, encodes a Mr 75,000 hyb

184 gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hy

185 e peripheral T-cell lymphomas--including one anaplastic large cell lymphoma--expressed CD95.

186 a possible mechanism for escape of cutaneous anaplastic large cell lymphoma from tumor regression.

187 a (ENKCL), and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher i

188 for select patients, particularly those with anaplastic large-cell lymphoma histology.

189 lifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibrobla

190 Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patie

191 Anaplastic large-cell lymphoma is associated with a chro

192 In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually ex

193 s highly expressed on Hodgkin's lymphoma and anaplastic large cell lymphoma, it is a promising target

194 n by small interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299.

195 More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are asso

196 n children with newly diagnosed nonlocalized anaplastic large cell lymphoma kinase (ALK)+/CD30+ ALCL.

197 nerated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered

198 signature was robust enough to differentiate anaplastic large cell lymphoma (n = 32) from other PTCLs

199 7), adult T-cell lymphoma/leukemia (n = 4), anaplastic large-cell lymphoma (n = 2), and extranodal n

200 This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung can

201 found in lympho-hematopoietic malignancies, anaplastic large cell lymphoma (NPM-ALK) and acute promy

202 esults 18 database examines the incidence of anaplastic large-cell lymphoma of the breast in the US f

203 tivating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblas

204 In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10

205 rontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PT

206 al translocation detected in the majority of anaplastic large cell lymphoma patients, and has recentl

207 urable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy an

208 sed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B

209 , including rhabdomyosarcoma, neuroblastoma, anaplastic large cell lymphoma, renal cell carcinoma, an

210 us carcinoma (SIR, 15.2; 95% CI, 13.0-17.7), anaplastic large cell lymphoma (SIR, 6.82; 95% CI, 4.53-

211 improvement, especially for people with non-anaplastic large-cell lymphoma subtypes.

212 gkin lymphoma, and NPM-ALK-rearranged T-cell anaplastic large cell lymphoma (T-ALCL), which are drive

213 ion and provided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5

214 xcluding anaplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was as

215 f lymphomatoid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting tha

216 rmed mycosis fungoides (T-MF), and cutaneous anaplastic large cell lymphoma were studied in parallel

217 -cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1

218 cases of Th2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for

219 itive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously t

220 kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic

221 oides, Sezary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression

222 o models of hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not b